Biotech News

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Nkarta (NKTX)Nkarta2026-06-25 13:46 ESTEarnings

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug.

Open original release

Related news

Nkarta

Nkarta is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States